IQE.L

IQE plc

£58.6 0.5B market cap April 15, 2026

IQE plc IQE.L BUFFETT / MUNGER / KLARMAN SUMMARY

1 SNAPSHOT

Price£58.6

Market Cap0.5B

2 BUSINESS

IQE possesses genuine technological leadership in compound semiconductor epitaxy with a 30-year IP portfolio and critical positioning in the VCSEL, photonics, and defence supply chains. However, the business has been structurally unprofitable since 2021, with cumulative losses exceeding £70M and shareholders' equity declining from £260M to £134M. The current share price of 58.6p (£468M market cap, ~4.8x FY2025 revenue) is entirely driven by takeover speculation following the Board's decision to seek buyers. For a value investor, this is a REJECT at current prices -- the probability-weighted fair value is approximately 18p, and the downside to 10-15p on a failed sale is severe. The technology has strategic value to a Coherent, Skyworks, or Asian semiconductor consolidator, but at current prices the market has already priced in an optimistic deal outcome.

3 MOAT NARROW

30+ years epitaxial process expertise, 54+ patents (QPC, cREO), 12-24 month customer qualification cycles, only independent epi house with MBE+MOCVD+CVD across three continents

4 MANAGEMENT

CEO: Jutta Meier

Poor - five years of losses, equity raises, convertible debt, and no strategic pivot until forced

5 ECONOMICS

-15.6% Op Margin

-12% ROIC

-17.7% ROE

-23.8x P/E

-0.005B FCF

17.5% Debt/EBITDA

6 VALUATION

FCF Yield-1.1%

DCF Range12 - 30

Overvalued by 95-388% - current price reflects takeover speculation, not fundamentals

7 MUNGER INVERSION

Kill Event	Severity	P()	E[Loss]
Strategic sale process failure - stock could retrace 65%+ to 15-25p if no buyer emerges	HIGH	-	-
Convertible loan note maturity - £21.2M repayment or 14% dilution at 15p conversion	MED	-	-

8 KLARMAN LENS

Downside Case

Strategic sale process failure - stock could retrace 65%+ to 15-25p if no buyer emerges

Why Market Right

Strategic review collapses with no acceptable offer; Convertible loan note maturity forces dilutive conversion or cash drain; HSBC withdraws credit facility or demands repayment; Major customer (Lumentum) qualifies alternative wafer supplier; Chinese GaAs competitors close quality gap in wireless

Catalysts

Successful sale of entire company at strategic premium to acquirer; Taiwan operations sale proceeds repay all debt, de-risk balance sheet; AI/datacenter photonics demand accelerates InP wafer revenue; Defence spending tailwind from US/NATO programme funding; Wireless recovery on next iPhone cycle / 5G Advanced refresh

9 VERDICT REJECT

C Quality Weak - HSBC covenant waivers required, £21.2M convertible loan notes maturing, equity halved in 4 years, surviving on external financing

Strong Buy£12

Buy£18

Fair Value£30

Do not buy at current price. Add to watchlist at 12-18p if strategic review fails and stock collapses.

🧠 ULTRATHINK Deep Philosophical Analysis

IQE plc (IQE.L) - Deep Philosophical Analysis

The Core Question: What Makes This Business Special?

There is a concept in semiconductor manufacturing that the general investing public rarely encounters: epitaxy. It refers to the controlled growth of crystalline layers on a substrate, atom by atom, with precision measured in angstroms. IQE has spent thirty years mastering this craft across multiple material systems -- gallium arsenide, indium phosphide, gallium nitride, gallium antimonide -- and across multiple growth techniques. This is not something you can learn from a textbook or replicate with capital expenditure alone. It is closer to a trade skill than a manufacturing process, more akin to the craft of a master glassblower than the operation of a silicon fab.

And therein lies both IQE's appeal and its fundamental weakness. The company sits at a critical juncture in the compound semiconductor supply chain. Every VCSEL in every iPhone's Face ID sensor traces its origin to an epitaxial wafer -- quite possibly one made by IQE. Every optical transceiver connecting servers in an AI datacenter relies on InP-based photonic chips that began life as an epitaxial wafer. Every infrared detector in a military night vision system uses compound semiconductor materials that IQE can produce.

The technology is real. The market position is real. The IP is real. And yet, the business has not earned a profit since 2020.

Moat Meditation: The Paradox of the Essential but Unprofitable Supplier

Charlie Munger often speaks of the difference between a good business and a good investment. IQE illustrates a less-discussed variant of this principle: the difference between a critical supplier and a profitable one.

IQE's customers cannot easily replace it. Qualification cycles of 12-24 months, the tacit knowledge embedded in crystal growth recipes, and the limited number of independent epi houses create genuine switching costs. For military and aerospace applications, the barriers are even higher -- security clearances, ITAR compliance, and the sheer conservatism of defense procurement mean that once IQE is designed in, it stays designed in.

But this criticality has not translated into pricing power or sustainable margins. The reasons are structural. First, IQE's largest end market -- wireless/mobile -- is dominated by a handful of customers (Lumentum, Coherent) who are themselves dependent on a single buyer (Apple). This creates a cascading concentration problem: Apple squeezes Lumentum on VCSEL pricing, Lumentum squeezes IQE on wafer pricing, and IQE absorbs the margin compression because it cannot afford to lose the volume.

Second, the compound semiconductor wafer business has high fixed costs (clean rooms, MBE reactors, MOCVD systems) and variable utilization. When mobile demand is strong, the fabs run full and margins look respectable (17% EBITDA in 2020). When demand collapses -- as it did in 2023-2024 with the inventory destocking cycle -- those fixed costs become an anchor, dragging margins into negative territory. IQE generated £4.3M EBITDA on £115M revenue in 2023. That is a 3.7% margin for a business that requires continuous capital investment in precision equipment. It is not enough.

Third, and most insidiously, the trend toward vertical integration by IQE's customers is a slow-moving but existential threat. Skyworks and Qorvo have already brought epitaxy in-house. If Coherent or Lumentum were to do the same for their VCSEL wafers, the floor would fall out from under IQE's wireless segment. The company's defense against this is its breadth of materials and techniques -- no single customer can replicate the full range of what IQE does -- but breadth without depth in any one high-margin niche is a recipe for mediocrity.

I rate this moat as narrow and narrowing. It exists, it is real, and in certain niches (defence, high-performance photonics) it may be durable. But in the core wireless business, it is under siege from both commoditization and vertical integration.

The Owner's Mindset: Would Buffett Own This for 20 Years?

Warren Buffett would not touch this business. It fails virtually every filter he applies: it does not generate consistent free cash flow, it has no pricing power, it requires continuous capital expenditure to maintain its competitive position, it is deeply cyclical, and its economics are hostage to the purchasing decisions of a single technology company (Apple) two steps removed in the supply chain.

Buffett has spoken about the "toll bridge" model -- businesses that sit at inevitable choke points and extract a toll from all comers. IQE sits at a choke point, yes, but it is a toll bridge where the tolls do not cover the cost of maintenance. The traffic is real, but the bridge is losing money.

More fundamentally, Buffett requires that a business demonstrate it can earn adequate returns on capital through a full cycle. IQE has not done this. Its best year in the past half-decade (2020) produced adjusted operating profit of just £5.4M on £260M of shareholders' equity -- a return of 2.1%. Its worst years have destroyed equity through persistent losses. This is not a business that compounds value over time. It is a business that consumes capital and hopes for better days.

The one exception to this assessment would be if IQE were acquired by a larger company that could provide the scale, financial backing, and customer diversification that the standalone business lacks. As a division of Coherent, Skyworks, or a well-capitalized Asian semiconductor group, IQE's technology would be far more valuable than it is as an independent entity. The IP, the customer qualifications, and the manufacturing knowhow are genuine assets -- they are simply trapped in a corporate structure that cannot monetize them.

Risk Inversion: What Could Destroy This Business?

The most obvious path to destruction is already well underway: the slow death by financial attrition. Equity has declined from £260M to £134M in four years. The company has issued equity (2023) and convertible debt (2025) to survive. The HSBC covenant waiver in Q4 2025 signals that the banking relationship is strained. If the strategic review fails to produce a buyer and the convertible loan notes must be repaid in cash, IQE could face a genuine liquidity crisis.

The second path is technological obsolescence. While compound semiconductors are essential today, the pace of innovation in silicon photonics and advanced packaging could eventually reduce the addressable market for standalone epitaxial wafers. Silicon photonics companies like Intel and GlobalFoundries are investing heavily in integrating photonic functions onto silicon, which could eventually erode demand for InP-based wafers.

The third path is the loss of the Apple VCSEL chain. If Apple decides to use a different sensing technology (radar, structured light alternatives) or if Lumentum/Coherent shift to alternative wafer suppliers, IQE's wireless revenue could collapse. The 52% decline in wireless revenue in H1 2025 shows how vulnerable this segment is.

Valuation Philosophy: Is Price Justified by Quality?

At 58.6p per share (£468M market cap), the market is valuing IQE at approximately 4.8 times its FY2025 revenue of ~£97M. For a loss-making company with negative free cash flow, deteriorating equity, and covenant waivers, this is an extraordinary valuation. It is explainable only through the lens of takeover speculation.

My probability-weighted fair value analysis yields approximately 18p per share. The current price requires a successful sale at a premium well above historical compound semiconductor M&A multiples. If the sale occurs at 2-3x revenue (the typical range for compound semiconductor assets), the implied share price would be 20-30p -- roughly half the current price.

This is not to say a deal cannot happen at a premium. Strategic acquirers sometimes pay above "fair" multiples for technology assets that complement their existing portfolios. But paying 58.6p for IQE is a bet that such a buyer exists and is willing to pay nearly 5x revenue for a money-losing business. That is speculation, not investing.

The Patient Investor's Path: When and How to Act

The disciplined approach is clear: do nothing at 58.6p. The price embeds a highly optimistic outcome that may not materialize. If the strategic review produces a firm offer, the shares would likely gap up further -- but the expected value calculation does not favor buying ahead of an uncertain binary event.

The opportunity for a patient investor arrives if the sale process fails. In that scenario, the stock could retrace to 15-25p as speculators exit. At 12-18p, IQE becomes interesting as an asset play with genuine optionality: the technology is valuable to a strategic acquirer, the AI/datacenter photonics tailwind is secular, and defence spending is structurally increasing. But you would need to accept that this is a special situation, not a compounding machine. You are buying the option, not the business.

If you want compound semiconductor exposure in a value framework, look at the acquirers, not the targets. Companies like Coherent, which have the scale and diversification to monetize epitaxial technology, are the better vehicles for this theme. IQE is the raw material -- valuable to the right buyer, but unable to refine itself into gold on its own.

Executive Summary

IQE plc is the world's leading independent manufacturer of compound semiconductor epitaxial wafers, headquartered in Cardiff, Wales. The company produces wafers across GaAs, InP, GaN, and GaSb material systems using MBE, MOCVD, and CVD technologies, serving wireless (5G/mobile), photonics (VCSELs, 3D sensing), defence, and AI/datacenter end markets. IQE has endured a brutal multi-year downturn -- revenue fell from £178M (2020) to £115M (2023), with cumulative adjusted losses exceeding £70M over 2021-2024. The company is now in an active strategic review including a potential sale of the entire company, with non-binding offers being negotiated as of early 2026.

Thesis in 3 sentences: IQE is a genuine technology leader in compound semiconductor epitaxy with 30+ years of IP and customer qualification barriers, but it is a structurally unprofitable business at current revenue levels and faces existential financial risk from £21.2M in convertible loan notes, net debt of £23.5M, and persistent operating losses. The stock has surged 12x from its 52-week low of 4.7p on takeover speculation and AI/datacenter demand recovery, making the current price of 58.6p a speculative bet on a successful sale rather than a value investment in a going concern. This is not a Buffett-style investment -- it is a special situation with significant downside if the sale process fails.

Phase 0: Opportunity Identification (Klarman)

Why Does This Opportunity Exist?

Takeover Premium / Strategic Review: IQE entered an official "offer period" in September 2025 after the board expanded its strategic review to include a potential sale. Non-binding offers for the whole group and individual assets (Taiwan operations) are being negotiated. The stock has rallied from sub-5p to nearly 60p on this speculation.
AI/Datacenter Tailwind: Photonics demand (VCSELs, silicon photonics) for AI datacenters is growing rapidly. IQE's InP and GaAs wafers are critical for optical transceivers. This secular tailwind has improved H2 2025 and Q1 2026 outlook.
Defence Spending Recovery: US military/defence programme funding releases in H2 2025 benefited IQE's GaN and infrared capabilities, with orders deferred from earlier periods.
Deep Cyclical Trough Recovery: The compound semiconductor industry experienced an unprecedented destocking cycle in 2023-2024. IQE's FY2025 revenue of ~£97M and improving order book suggest recovery is underway.

This is a takeover speculation / deep cyclical recovery play -- not a classic value investment. The business does not generate free cash flow at current scale and has not been sustainably profitable since 2020.

Phase 1: Risk Analysis (Inversion)

How Could This Investment Lose 50%+ Permanently?

Strategic Sale Fails: If no acquirer emerges at an acceptable price, the stock could retrace to 15-25p. With £21.2M in convertible loan notes maturing (originally March 2026, extendable 6 months), a failed sale combined with weak trading could trigger a liquidity crisis.
Convertible Loan Note Dilution: The CLN converts at 15p per share. If converted, this would issue ~141M new shares (14% dilution on 979M shares). If not converted, IQE must repay £21.2M in cash it may not have.
Persistent Operating Losses: IQE has lost money on an adjusted basis every year since 2021. Adjusted operating losses: -£6.5M (2021), -£3.6M (2022), -£20.2M (2023), -£18.4M (2024). The business model may be structurally broken at sub-£150M revenue.
Customer Concentration: IQE's wireless revenue is heavily tied to the VCSEL supply chain for Apple's 3D sensing (via Lumentum and Coherent, who hold 80% of the VCSEL market). Apple internalizing or diversifying wafer supply would be devastating.
Commodity Risk: Despite qualification barriers, epitaxial wafers face long-term commoditization pressure as Chinese competitors (particularly in GaAs) build capacity. Win Semiconductor (Taiwan) is a formidable competitor.
Balance Sheet Fragility: Net debt of £23.5M (H1 2025), HSBC covenant waivers required in Q4 2025, and the CLN creating a £21.2M debt wall. Shareholders' equity has eroded from £260M (2020) to £134M (2024).

Bear Case (3 Sentences)

IQE is a subscale compound semiconductor wafer manufacturer that has destroyed shareholder value for five consecutive years, with cumulative losses exceeding £70M and shareholders' equity declining by nearly 50%. The current share price of 58.6p reflects takeover speculation rather than fundamental value -- if the sale process collapses, the stock would revert to 15-25p, representing a 60-75% loss. With convertible loan notes maturing imminently and no clear path to profitability without scale or a buyer, this is a value trap disguised as a turnaround story.

Risk Register

Risk	Probability	Impact	Expected Loss
Strategic sale process fails	35%	-65%	-22.8%
CLN dilution / cash repayment crisis	25%	-40%	-10.0%
Wireless demand remains weak (Apple/VCSEL)	30%	-25%	-7.5%
Chinese competitor gains share	20%	-20%	-4.0%
Revenue recovery stalls below breakeven	25%	-35%	-8.8%
Total Expected Loss			-53.0%

Sell Triggers (Pre-Defined)

Strategic review concludes with no sale and no credible standalone plan
HSBC revokes credit facility or demands full repayment
CLN holders demand cash repayment and company cannot fund it
Revenue falls below £80M annualized for two consecutive quarters
Key customer (Lumentum) shifts wafer supply to competitor

Phase 2: Financial Analysis

Income Statement Analysis (5 Years)

Year	Revenue (£M)	EBITDA (£M)	EBITDA Margin	Adj Op P/L (£M)	Adj EPS	FCF (£M)
2020	178.0	30.1	16.9%	5.4	0.29p	23.6
2021	154.1	18.7	12.1%	(6.5)	(2.41p)	(1.6)
2022	167.5	23.4	14.0%	(3.6)	(0.74p)	4.1
2023	115.3	4.3	3.7%	(20.2)	(2.68p)	(3.1)
2024	118.0	8.1	6.9%	(18.4)	(2.46p)	(4.9)
2025E	~97.0	~2.0	~2.1%	~(15)	~(1.8p)	~(5)

Key Observations:

Revenue has declined 45% from the 2020 peak of £178M to ~£97M in FY2025
The business has not generated positive adjusted operating profit since 2020
EBITDA margins have compressed from 17% to ~2%, indicating severe under-utilization of manufacturing capacity
Free cash flow has been negative in 4 of the last 5 years
The company has been surviving on equity raises (£29.8M in 2023) and convertible debt (£18M in 2025)

Segment Performance

Segment	FY2024 (£M)	FY2023 (£M)	H1 2025 (£M)	H1 2024 (£M)	Trend
Wireless	67.3	53.9	18.6	38.8	Severe H1 2025 decline (-52%)
Photonics	49.9	59.1	26.6	26.8	Stabilizing, AI upside
CMOS++	0.8	2.3	n/a	n/a	Immaterial

The wireless segment (57% of FY2024 revenue) is highly cyclical and dependent on the mobile handset cycle, particularly Apple's VCSEL demand chain. The photonics segment showed resilience and is benefiting from AI/datacenter buildout. H2 2025 saw recovery in both segments.

Balance Sheet Analysis

Metric	FY2020	FY2022	FY2023	FY2024	H1 2025
Cash (£M)	n/a	n/a	5.6	4.7	17.0
Adj Net Debt (£M)	(1.9)	15.2	2.2	18.8	23.5
Shareholders' Equity (£M)	260.4	175.1	169.8	134.1	~115
Shares (M)	~800	~800	~900	~979	~979

Critical Balance Sheet Issues:

Shareholders' equity has been halved in 4 years through persistent losses
Net debt has ballooned from near-zero to £23.5M
The £21.2M convertible loan note (15p conversion, 12-month maturity + 6-month extension) creates a debt wall
HSBC covenant waiver needed for Q4 2025 -- indicates the business is operating at the edge of its banking facilities
Cash of £17M (H1 2025) includes £18M CLN proceeds -- organic cash generation is negligible

Capital Structure Red Flags

The convertible loan notes are particularly concerning:

Face value: £21.2M (issued at 15% discount, so £18M cash received)
Conversion price: 15p per share (current price 58.6p -- deep in the money)
Zero coupon but 9% redemption premium if extended
Security: Secured against UK assets, subordinated to HSBC facility
If converted: ~141M new shares, 14% dilution
If not converted: £21.2M cash repayment required (potentially £23.1M with premium)

Phase 3: Moat Assessment

Moat Sources

Epitaxial Process Expertise (30+ years): IQE has accumulated deep know-how in growing compound semiconductor crystals layer by layer. This is genuinely difficult to replicate -- the process involves controlling crystal growth at atomic-layer precision across multiple material systems (GaAs, InP, GaN, GaSb).
Customer Qualification Barriers: Qualification of a new epitaxial wafer supplier typically takes 12-24 months and requires extensive testing. Once qualified, customers are reluctant to switch, creating moderate switching costs.
IP Portfolio: 54+ patents covering Quasi Photonic Crystals, cREO technology, and various epitaxial processes. 30 years of trade secrets in crystal growth recipes.
Manufacturing Scale: Operations across three continents (UK, US, Taiwan) with MBE, MOCVD, and CVD capabilities. The breadth of technology platforms is unmatched among independent epi houses.
Critical Supply Chain Position: For certain niche applications (military infrared, high-performance VCSELs), IQE may be one of very few qualified suppliers globally.

Moat Assessment: NARROW (and narrowing)

Width: Narrow The moat exists primarily through qualification barriers and accumulated process expertise, not through structural economic advantages like network effects or cost leadership. IQE's moat is real but fragile -- it depends on customers choosing not to vertically integrate (which Skyworks and Qorvo have done) and on Chinese competitors not closing the quality gap (which they are gradually doing).

Durability: 5-10 years In wireless/mobile, the moat is narrowing as Chinese GaAs epi houses improve quality. In photonics and defence, the moat is more durable due to higher specification requirements and security clearance needs.

Trend: Narrowing in wireless, stable in photonics/defence The shift toward AI/datacenter photonics may actually strengthen IQE's position if it can capture share in InP-based optical transceiver wafers. However, the wireless business (still the majority of revenue) faces long-term commoditization pressure.

Phase 4: Synthesis and Valuation

Valuation Approach 1: Asset / Replacement Value

IQE's manufacturing equipment (MBE reactors, MOCVD systems, clean room infrastructure) would cost significantly more to replicate than the current market cap implies:

Shareholders' equity: ~£134M (FY2024 book value)
PP&E is significant for a wafer fab operation
Estimated replacement cost of manufacturing assets: £150-250M
IP portfolio value: £20-50M (54+ patents, 30 years of trade secrets)
Asset-based fair value: 20-35p per share (accounting for net debt and losses)

At 58.6p, the stock is trading ABOVE asset-based fair value -- the premium reflects takeover speculation.

Valuation Approach 2: DCF on Recovery Scenario

Bull case recovery assumptions:

Revenue recovers to £140M by FY2028 (still below 2020 peak)
EBITDA margins recover to 12% (£16.8M)
CapEx normalized at £10M
FCF of ~£7M
Terminal multiple: 8x EBITDA = £134M enterprise value
Less net debt: ~£115M equity value = ~12p per share

Aggressive bull case (sale/AI boom):

Revenue reaches £180M by FY2028
EBITDA margins at 15% (£27M)
10x EBITDA = £270M enterprise value
Less net debt: ~£250M equity value = ~25p per share

Even in the aggressive bull case for the standalone business, DCF analysis does not support the current 58.6p price.

Valuation Approach 3: Private Market / M&A Comps

This is the only framework that can justify the current price:

Coherent (II-VI) acquisition of Finisar: ~3x revenue for photonics assets
Compound semiconductor M&A: Typically 1.5-3x revenue for profitable players, 0.5-1.5x for loss-making
IQE at 1.5x FY2025 revenue (~£97M) = £145M = ~15p per share
IQE at 2.5x FY2025 revenue = £242M = ~25p per share
IQE at 3x revenue (aggressive, assumes strategic premium) = £291M = ~30p per share

Current market cap of £468M implies ~4.8x FY2025 revenue -- this would require a strategic acquirer to pay a significant control premium well above industry norms.

Entry Price Analysis

Scenario	Price	Implied Valuation	Probability
Takeover at strategic premium (3-4x rev)	30-40p	£290-390M EV	25%
Takeover at fair value (2-2.5x rev)	20-25p	£195-245M EV	20%
No takeover, recovery to profitability	15-20p	10-12x normalized FCF	25%
No takeover, continued losses	5-10p	Asset value less losses	30%
Probability-weighted fair value	~18p

Entry Prices (for contrarian/special situation investors)

Strong Buy: 12p (asset value with margin of safety)
Accumulate: 18p (probability-weighted fair value)
Current price: 58.6p (225% above accumulate price -- pure takeover speculation)

Conclusion

IQE is a genuinely important company in the compound semiconductor supply chain, with real technology, real IP, and real qualification barriers. However, it is a structurally unprofitable business at current revenue levels, with a deteriorating balance sheet, significant debt maturities, and no clear path to self-sustaining profitability without either a dramatic revenue recovery or a sale to a larger acquirer.

The current share price of 58.6p (market cap ~£468M) is entirely driven by takeover speculation and prices in a highly optimistic outcome from the strategic review. At nearly 5x revenue for a loss-making business, the market is pricing in a deal that may never materialize -- or if it does, may occur at a price well below the current level.

Verdict: REJECT at current price. This is not a value investment -- it is a binary bet on a takeover. The risk/reward is unfavorable for a patient, value-oriented investor. If the stock were to retrace to 12-18p on a failed sale process, it would become interesting as an asset play with optionality on compound semiconductor demand recovery.

Analysis based on: FY2024 Annual Results, H1 2025 Interim Results, September 2025 Trading Update, January 2026 Trading Update, IQE corporate website, Compound Semiconductor News.